Search results

Skip to results

Type

Status

Last updated

Showing 1 to 6 of 6 results for ertugliflozin

  1. Ertugliflozin as monotherapy or with metformin for treating type 2 diabetes (TA572)

    Evidence-based recommendations on ertugliflozin (Steglatro) as monotherapy or with metformin for treating type 2 diabetes in adults.

    Technology appraisal guidance
    Published
    27 March 2019
    View recommendations

    Sections for TA572

  2. Ertugliflozin with metformin and a dipeptidyl peptidase-4 inhibitor for treating type 2 diabetes (TA583)

    Evidence-based recommendations on ertugliflozin (Steglatro) with metformin and a dipeptidyl peptidase-4 inhibitor for treating type 2 diabetes in adults.

    Technology appraisal guidance
    Published
    5 June 2019
    View recommendations

    Sections for TA583

  3. Sparsentan for treating primary IgA nephropathy [ID6308]

    In development [GID-TA11359] Expected publication date: 25 June 2025

    Technology appraisal guidance
    In development

  4. Type 2 diabetes in adults: management (NG28)

    This guideline covers care and management for adults (aged 18 and over) with type 2 diabetes. It focuses on patient education, dietary advice, managing cardiovascular risk, managing blood glucose levels, and identifying and managing long-term complications.

    NICE guideline
    Last updated
    29 June 2022
    View recommendations

    Sections for NG28

  5. Targeted-release budesonide for treating primary IgA nephropathy (review of TA937) [ID6485]

    In development [GID-TA11662] Expected publication date: 17 December 2025

    Technology appraisal guidance
    In development

  6. Insulin icodec for treating type 2 diabetes [ID6175]

    In development [GID-TA11104] Expected publication date: TBC

    Technology appraisal guidance
    In development